TY - JOUR
T1 - Homotypic and Heterotypic Protection and Risk of Reinfection following Natural Norovirus Infection in a Highly Endemic Setting
AU - Chhabra, Preeti
AU - Rouhani, Saba
AU - Browne, Hannah
AU - Peñataro Yori, Pablo
AU - Siguas Salas, Mery
AU - Paredes Olortegui, Maribel
AU - Moulton, Lawrence H.
AU - Kosek, Margaret N.
AU - Vinjé, Jan
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2021/1/15
Y1 - 2021/1/15
N2 - Background: Norovirus is a leading cause of acute gastroenteritis worldwide, yet there is limited information on homotypic or heterotypic protection following natural infection to guide vaccine development. Methods: A total of 6020 stools collected from 299 Peruvian children between 2010 and 2014 were tested by norovirus real-time reverse-transcription polymerase chain reaction followed by sequence-based genotyping. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) of infection among children with vs without prior exposure. Results: Norovirus was detected in 1288 (21.3%) samples. GII.4 (26%), GII.6 (19%), and GI.3 (9%) viruses accounted for 54% of infections. Homotypic protection for GI.3 (HR, 0.35; P=.015), GI.7 (HR, 0.19; P=.022), GII.4 (HR, 0.39; P<.001), and GII.6 (HR, 0.52; P=.006) infections was observed. Hazard analysis showed that children with prior GII.4 infection exhibited heterotypic protection with a 48% reduction of subsequent GI.3 infection (HR, 0.52; P=.005). Prior exposure to GI.3, GII.2, and GII.17 infections enhanced susceptibility to subsequent infections with several other norovirus genotypes. Conclusions: Children up to 2 years of age infected with GII.4 noroviruses demonstrated both homotypic and heterotypic protection to reinfection with other genotypes. These data support the need for ongoing vaccine development efforts with GII.4 as the main component and caution the inclusion of genotypes that may enhance susceptibility to infections.
AB - Background: Norovirus is a leading cause of acute gastroenteritis worldwide, yet there is limited information on homotypic or heterotypic protection following natural infection to guide vaccine development. Methods: A total of 6020 stools collected from 299 Peruvian children between 2010 and 2014 were tested by norovirus real-time reverse-transcription polymerase chain reaction followed by sequence-based genotyping. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) of infection among children with vs without prior exposure. Results: Norovirus was detected in 1288 (21.3%) samples. GII.4 (26%), GII.6 (19%), and GI.3 (9%) viruses accounted for 54% of infections. Homotypic protection for GI.3 (HR, 0.35; P=.015), GI.7 (HR, 0.19; P=.022), GII.4 (HR, 0.39; P<.001), and GII.6 (HR, 0.52; P=.006) infections was observed. Hazard analysis showed that children with prior GII.4 infection exhibited heterotypic protection with a 48% reduction of subsequent GI.3 infection (HR, 0.52; P=.005). Prior exposure to GI.3, GII.2, and GII.17 infections enhanced susceptibility to subsequent infections with several other norovirus genotypes. Conclusions: Children up to 2 years of age infected with GII.4 noroviruses demonstrated both homotypic and heterotypic protection to reinfection with other genotypes. These data support the need for ongoing vaccine development efforts with GII.4 as the main component and caution the inclusion of genotypes that may enhance susceptibility to infections.
KW - GII.4
KW - heterotypic protection
KW - homotypic protection
KW - norovirus
KW - reinfection
UR - http://www.scopus.com/inward/record.url?scp=85100583239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100583239&partnerID=8YFLogxK
U2 - 10.1093/cid/ciaa019
DO - 10.1093/cid/ciaa019
M3 - Article
C2 - 33501947
AN - SCOPUS:85100583239
SN - 1058-4838
VL - 72
SP - 222
EP - 229
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 2
ER -